Huntington's
The latest sourced reporting on Huntington's from Dementias Today: dated, and plain about what the evidence does and does not show.
Governor Kathy Hochul has signed a law forcing New York's long-term care hotline, NY Connects, to actively point callers toward Alzheimer's and dementia programs rather than leaving them to ask. The catch: nothing changes for a full year.
An open-access review in Advanced Healthcare Materials catalogues the nanoparticles engineered to carry drugs all the way to failing mitochondria in neurodegeneration, and states on its own first pages that none has been approved for anyone.
The Massachusetts House voted unanimously on July 29, 2026 to require acute care hospitals to notify a designated family member or caregiver soon after a dementia patient is admitted and again before discharge. The bill, which also expands diagnosis notification and creates a new MassHealth care coordination benefit, now heads to the Senate.
A regional midterm review of the UN Decade of Healthy Aging finds that the share of countries in the Americas with a national long-term-care policy jumped from 61 percent to 88 percent since 2020, but the money and services to make those policies real have not kept pace, with direct consequences for how dementia care gets funded and staffed.
NestaCell, a therapy grown from the pulp of children's milk teeth, beat placebo on motor scores in a 35-person Brazilian study. The 120-person trial meant to confirm it is registered, unstarted on paper, and silent since 2023.
A newly disclosed four-year readout of uniQure's gene therapy ifezuntirgene inilparvovec showed the trial's main statistical measure fell short of significance, reigniting questions about the small study's external comparison group even as the company's regulatory filing rests on earlier data.
A statistics preprint from UNC Chapel Hill and Wake Forest puts four widely used models of time to Huntington's diagnosis through an external test in Enroll-HD data, using metrics built for cohorts where more than 80 percent of participants leave the study still undiagnosed.
uniQure has submitted a Biologics License Application for its one-time gene therapy AMT-130, asking the FDA for accelerated approval on the strength of 3-year data the agency had rejected as insufficient six months earlier.
The National Institute on Aging has published the finalized report from its fourth triennial Dementia Care and Caregiving Research Summit, naming five research areas and a list of gaps it wants filled next, including a fresh estimate that dementia now costs the country up to $800 billion a year.
A mouse study led by Lawrence Berkeley National Laboratory finds widespread breaks in DNA strands, separate from the disease's hallmark repeat expansion, kill brain cells, and that an experimental antioxidant compound reversed the damage in mice.
A clinical trials review from UCL's Huntington's Disease Centre has published the 36-month topline results for uniQure's gene therapy AMT-130, the same dataset the FDA has since agreed can support a US filing, along with the trial's fullest account yet of its limits.
Registry records show the worldwide half of Skyhawk Therapeutics' FALCON-HD programme recruiting since January, with the Australia and New Zealand study closed at 144 participants and up to 400 more sought. No placebo-controlled results exist yet.
Amsterdam UMC researchers interviewed 14 pairs, the person with the diagnosis and the family member caring for them, about impaired awareness in dementia, Huntington's disease and Korsakoff's syndrome. Both sides were in the room, and they described two different lives.
Sarepta's SRP-1005 is being tested at two New Zealand sites in a Phase 1 study that measures safety and drug levels, not benefit. Dosing began in May.
REGEN4HD, registered as NCT07451613, is implanting embryonic stem cell-derived neural stem cells into the striatum of 21 people with early Huntington's. It is a safety study, and the field it grew out of is a long lesson in patience.
A small qualitative study from Beaumont and Limerick asked family carers of people with Huntington's disease what the job feels like. The genetic dread they described was real, but it pointed at their children, not at themselves.
A new European interview study asks people with Huntington's disease and their family caregivers what the household absorbs. The answers are unsurprising to families and inconvenient for care systems. The funder, F. Hoffmann-La Roche, set the study's scope.
Interviews with 13 psychologists working in Netherlands Huntington's services set out what psychological support consists of from the at-risk years to the nursing home, and where it runs into limits: cognitive change, lack of disease awareness, and referrals that go nowhere useful.
Top-line results from the phase 2 GENERATION HD2 trial show tominersen lowered mutant huntingtin and neurofilament light in spinal fluid over about 16 months without slowing measured progression; the first-in-human study of RG6496 was stopped for separate reasons arising in animals.
A preprint posted to bioRxiv on June 8, 2026 by a Massachusetts General Hospital group reports that knocking out the mismatch repair gene Msh3 in the striatum of Huntington's model mice at three different ages slowed further CAG repeat expansion and reduced molecular and histological signs of disease, with the largest effect when editing was done earliest. The work is in mice, and it has not been peer reviewed.
A Nature paper from UC San Diego and German teams reports that a small class of cortical inhibitory cells falls nearly silent in two Huntington's mouse models, and that switching those cells back on with optogenetics eased motor deficits for days. The work is in mice only.
The Five-Star Technical Users' Guide says that from the April 2026 refresh every long-stay resident with a history of schizophrenia is dropped from the publicly reported antipsychotic measure, weeks after a federal watchdog said the diagnosis had been used to hide prescribing.
INVEST-HD, registered as NCT07326709, is enrolling 770 people with early symptomatic Huntington's disease to compare votoplam against placebo, after interim extension results measured against an outside comparison group rather than a placebo arm.
The FDA has told the company that the roughly three-year analysis of its phase 1/2 striatal gene therapy AMT-130, which reported 75 percent slowing on a composite rating scale in 12 high-dose patients against an external control, can be the primary basis for an accelerated-approval application. The filing is planned for this quarter, and a confirmatory trial would still be required.
An HHS Inspector General review of 40 federal inspections found diagnoses added to charts of residents given antipsychotics, often without telling the family. What the finding covers, and what it does not.